Early experience with conversion to sirolimus in a pediatric renal transplant population

Pediatric Nephrology

Volumn 22, Issue 10, 2007, Pages 1773-1777

  Powell, Harley R ^a   Kara, Tonya ^b   Jones, Colin L ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b STARSHIP CHILDREN S HOSPITAL   (New Zealand)

Author keywords

Calcineurin inhibitors; Glomerularfiltration rate; Mycophenolate; Nephrotoxicity; Pediatric renal transplantation; Sirolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIMB PAIN; LOADING DRUG DOSE; LONG TERM CARE; MOUTH ULCER; MYALGIA; PANCYTOPENIA; PEDIATRIC SURGERY; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS REACTIVATION;

CHILD; GLOMERULAR FILTRATION RATE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548302081     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0571-6     Document Type: Article

References (16)

1. Kahan BD (1999) The potential role of rapamycin in pediatric transplantation as observed from adult studies. Pediatr Transplant 3:175-180
2. Sehgal SN (2003) Sirolimus: Its discovery, biological properties and mechanisms of action. Transplant Proc 35(Suppl):7S-14S
3. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR (2004) De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4:1776-1785
4. Gregory C, Hum P, Billingham ME, Morris RE (1993) Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation 55:1409-1418
5. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135
6. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M (2003) Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63:917-926
7. Campistol J, Eris J, Oberbauer R, Friend P, Hutchinson B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Sarcola JA, Neylan JF (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17:581-589
8. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyo JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapimune Maintenance Study Group (2005) Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18:22-29
9. Pussell B, Russ G, Walker R, Campbell S, O'Connell P, Kanellis J, Eris J (2006) Efficacy and safety of conversion from calcineurin inhibitors to sirolimus verus continued use of calcineurin inhibitors in renal allograft recipients: Results of the Convert trial. Nephrology 11(Suppl):A35
10. Hymes LC, Warshaw BL (2005) Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 9:520-522
11. Kreis H, Cisterne J, Land W, Wramner L, Squifflet J, Abramowicz D, Campistol J, Morales J, Grinyo J, Mourad G, Berthoux F, Brattstrom C, Lebranchu P, Vialtel P (2000) Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69:1252-1260
12. Groth CG, Backman L, Morales J, Calne R, Kreis H, Lang P, Touraine J, Claesson K, Campistol J, Durand D, Wramner L, Brattstrom C, Charpentier B (1999) Sirolimus (Rapamycin)-based therapy in human renal transplantation; similar efficacy and different toxicity compared with cyclosporine. Transplantation 67:1036-1042
13. Flechner SM, Goldfarb D, Feng J, Krishnamurthi V, Modlin C, Mastroianni B, Savas K, Cook D, Novick A (2002) Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070-1076
14. Picard N, Premaud A, Rousseau A, LeMeur Y, Marquet P (2006) A comparison of the effect of ciclosporin and sirolimus on the pharmacokinetics of mycophenolate in renal transplant patients. Br J Clin Pharmacol 62:477-484
15. CTS Collaborative Transplant Study, http://www.ctstransplant.org Graphic E-11001-0207
16. Deikmann F, Campistol J (2006) Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy; benefits and risks. Nephrol Dial Transplant 21:562-568